Quintiles has rewired its risk-based monitoring service to include analytics technology the CRO says can better predict pressure points in clinical trials, touting its new offering as the first of its kind.
Scientists in Scotland have been grabbing headlines with news that their preclinical research into an experimental single-dose antimalaria compound has shown real promise, spurring Merck KGaA to pick up the development and commercialization rights.
Researchers at the National Institutes of Health reported that a leishmaniasis vaccine based on sand fly saliva has worked well in monkeys.
MultiClonal Therapeutics has been awarded a $750,000 grant to develop personalized therapies for chronic lung diseases like COPD.
Eli Lilly inked a pair of deals with Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute to hit the gas on oncology R&D, aiming to shorten the development process for a slew of new medicines.
India's GVK BioSciences, marred by a data scandal, has signed an exclusive deal with Swedish drug developer Medivir, agreeing to handle the bulk of the biotech's chemistry work.
The struggling GlaxoSmithKline is committing more than $95 million in cash and added resources over the next 5 years to launch a new nonprofit institute in Seattle that will explore the "living genome" for new insights into the ways that cells function in search of a new generation of drugs to put into the clinic.
The biopharma industry has worked for decades to find an effective treatment for acute ischemic stroke with minimal success. At least 5 clinical trials over a recent 6-month period have now found that removing clots using a class of devices known as stent retrievers is an effective treatment for stroke.
Last spring, as Aerie Pharmaceuticals execs rushed to man the ramparts as its share price tanked following the failure of its glaucoma drug Rhopressa, the company insisted that a slight change to its late-stage program would have been enough to get them over the goal line. So this morning, in a head-snapping turnaround, shares jumped 50% as the FDA proved amenable to making some changes that might let another Phase III trial succeed.
Kite Pharma, at work on therapies that use the immune system to fight cancer, paired up with Adimab to expand its R&D efforts.